



## Treatment of Orthopoxvirus Infections

Guest Editor:

**Dr. Panayampalli Subbian  
Satheshkumar**

Poxvirus and Rabies Branch,  
Centers for Disease Control and  
Prevention, Atlanta, GA, USA

Deadline for manuscript  
submissions:

**closed (15 February 2021)**

### Message from the Guest Editor

Dear Colleagues,

Smallpox remains the only human disease completely eradicated through a successful vaccination campaign. As routine smallpox vaccination of the general public was discontinued, the majority of the current population are naive to orthopoxvirus infection. Human orthopoxvirus infections are predominantly caused by monkeypox virus in Africa, cowpoxvirus in Europe, vaccinia virus in South America, and buffalopoxvirus in Asia. Due to the smallpox adverse effects caused by the replication of the competitive vaccinia virus in contraindicated individuals, a safer non-replicative vaccine was recently approved by the Food and Drug Administration (FDA). TPOXX was approved for smallpox treatments by FDA recently. There is a need for additional antivirals that target different steps in the orthopoxvirus lifecycle. Similarly, prophylactic treatment with antibodies against orthopoxviruses is needed. We hope this Special Issue will cover several of these important topics for treatment of orthopoxvirus infections.

Dr. Panayampalli Subbian Satheshkumar  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)